Onychomycosis and tinea pedis in patients with diabetes

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Severe LE bacterial infection with resultant amputation in persons with diabetes is costly both in terms of health care use and loss of productivity from morbidity, mortality, and disability. Although there are no long-term prospective studies that prove onychomycosis treatment prevents serious sequelae, common sense suggests that preserving the cutaneous integrity of the LE is useful for the compromised patient with diabetes. A recent study shows that oral agents such as terbinafine can effectively treat and cure onychomycosis and concomitant skin infection (dermatophytosis) in patients with diabetes. The cost savings from prevention of LE complications is significant, making the expense and effort needed to treat onychomycosis and tinea pedis in patients with diabetes a sound investment. LE amputation in individuals with diabetes is the primary cause of disability and death in this population. Education of such patients about the importance of foot and nail care is paramount.

Original languageEnglish (US)
Pages (from-to)S130-S134
JournalJournal of the American Academy of Dermatology
Volume43
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Tinea Pedis
Onychomycosis
terbinafine
Amputation
Skin
Tinea
Cost Savings
Patient Education
Nails
Bacterial Infections
Foot
Cause of Death
Prospective Studies
Morbidity
Delivery of Health Care
Mortality
Infection
Population
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Onychomycosis and tinea pedis in patients with diabetes. / Rich, Phoebe.

In: Journal of the American Academy of Dermatology, Vol. 43, 01.01.2000, p. S130-S134.

Research output: Contribution to journalArticle

@article{8aed7b8ffeff4099864ca6dc329ab232,
title = "Onychomycosis and tinea pedis in patients with diabetes",
abstract = "Severe LE bacterial infection with resultant amputation in persons with diabetes is costly both in terms of health care use and loss of productivity from morbidity, mortality, and disability. Although there are no long-term prospective studies that prove onychomycosis treatment prevents serious sequelae, common sense suggests that preserving the cutaneous integrity of the LE is useful for the compromised patient with diabetes. A recent study shows that oral agents such as terbinafine can effectively treat and cure onychomycosis and concomitant skin infection (dermatophytosis) in patients with diabetes. The cost savings from prevention of LE complications is significant, making the expense and effort needed to treat onychomycosis and tinea pedis in patients with diabetes a sound investment. LE amputation in individuals with diabetes is the primary cause of disability and death in this population. Education of such patients about the importance of foot and nail care is paramount.",
author = "Phoebe Rich",
year = "2000",
month = "1",
day = "1",
doi = "10.1067/mjd.2000.110376",
language = "English (US)",
volume = "43",
pages = "S130--S134",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Onychomycosis and tinea pedis in patients with diabetes

AU - Rich, Phoebe

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Severe LE bacterial infection with resultant amputation in persons with diabetes is costly both in terms of health care use and loss of productivity from morbidity, mortality, and disability. Although there are no long-term prospective studies that prove onychomycosis treatment prevents serious sequelae, common sense suggests that preserving the cutaneous integrity of the LE is useful for the compromised patient with diabetes. A recent study shows that oral agents such as terbinafine can effectively treat and cure onychomycosis and concomitant skin infection (dermatophytosis) in patients with diabetes. The cost savings from prevention of LE complications is significant, making the expense and effort needed to treat onychomycosis and tinea pedis in patients with diabetes a sound investment. LE amputation in individuals with diabetes is the primary cause of disability and death in this population. Education of such patients about the importance of foot and nail care is paramount.

AB - Severe LE bacterial infection with resultant amputation in persons with diabetes is costly both in terms of health care use and loss of productivity from morbidity, mortality, and disability. Although there are no long-term prospective studies that prove onychomycosis treatment prevents serious sequelae, common sense suggests that preserving the cutaneous integrity of the LE is useful for the compromised patient with diabetes. A recent study shows that oral agents such as terbinafine can effectively treat and cure onychomycosis and concomitant skin infection (dermatophytosis) in patients with diabetes. The cost savings from prevention of LE complications is significant, making the expense and effort needed to treat onychomycosis and tinea pedis in patients with diabetes a sound investment. LE amputation in individuals with diabetes is the primary cause of disability and death in this population. Education of such patients about the importance of foot and nail care is paramount.

UR - http://www.scopus.com/inward/record.url?scp=0033754726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033754726&partnerID=8YFLogxK

U2 - 10.1067/mjd.2000.110376

DO - 10.1067/mjd.2000.110376

M3 - Article

C2 - 11044289

AN - SCOPUS:0033754726

VL - 43

SP - S130-S134

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

ER -